PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsGa68
Ga68
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
132 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MeningiomaD008579EFO_0003098D32.922—116
MedulloblastomaD008527——13—115
ParagangliomaD010235——12—1—3
Pituitary neoplasmsD010911————11—2
Central nervous system neoplasmsD016543—————1—1
AdenomaD000236—————1—1
HemangioblastomaD018325—————1—1
Olfactory esthesioneuroblastomaD018304EFO_1000407————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471—C61142912—1863
CarcinomaD002277—C80.09101—121
NeoplasmsD009369—C80694—317
AdenocarcinomaD000230——192—214
Castration-resistant prostatic neoplasmsD064129——294——12
RecurrenceD012008——246—211
Lung neoplasmsD008175HP_0100526C34.90111—24
Pituitary diseasesD010900—E23.7——1——1
Non-small-cell lung carcinomaD002289———11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuroendocrine tumorsD018358EFO_1001901D3A.876——313
Hepatocellular carcinomaD006528—C22.053——210
Liver neoplasmsD008113EFO_1001513C22.053——210
Breast neoplasmsD001943EFO_0003869C5042——15
NeuroblastomaD009447EFO_0000621—34———5
Carcinoid tumorD002276—D3A.0033———4
GliomaD005910EFO_0000520——1——23
Thyroid neoplasmsD013964EFO_0003841—12———3
Pancreatic neoplasmsD010190EFO_0003860C2522———3
LymphomaD008223—C85.9—2——13
Show 20 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD012509——3———14
Brain neoplasmsD001932EFO_0003833C711———12
CholangiocarcinomaD018281—C22.12————2
Ovarian neoplasmsD010051EFO_0003893C561———12
Esophageal neoplasmsD004938—C152————2
Coronary artery diseaseD003324—I25.12————2
Endocrine gland neoplasmsD004701EFO_0003769D351————1
Von hippel-lindau diseaseD006623—Q85.831————1
Multiple endocrine neoplasia type 1D018761—E31.211————1
Multiple endocrine neoplasiaD009377—E31.21————1
Show 29 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlioblastomaD005909EFO_0000515—————22
AstrocytomaD001254EFO_0000271—————22
OligodendrogliomaD009837EFO_0000631—————22
InflammationD007249MP_0001845—————22
Islet cell adenomaD007516EFO_0007331D13.7————11
GliosarcomaD018316——————11
Solitary fibrous tumorsD054364——————11
Acoustic neuromaD009464HP_0009588—————11
EpendymomaD004806——————11
Ewing sarcomaD012512EFO_0000173—————11
Show 25 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name—
INN—
Description
—
Classification
Unknown
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL ID—
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID—
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use